Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors
Feb 16, 2023
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
COVID-19 mRNA vaccines safe during pregnancy
Feb 13, 2024
In a large study, there were lower odds of neonatal mortality associated with vaccination.
COVID-19 vaccination bests natural immunity for cutting death, hospitalizations
Dec 28, 2022
Natural immunity, however, was tied to a lower incidence of new infection.
COVID-19 vaccine protection lasts at least six months after second dose
Feb 07, 2023
Vaccine effectiveness against death was lower for patients aged 80 years and older.
Vaccination cuts risk for myocardial infarction, stroke after COVID-19
Jul 29, 2022
The findings show a lower hospitalization risk 31 to 120 days after COVID-19 infection.
FDA approves first RSV vaccine
May 03, 2023
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
Age, cancer type affect COVID-19 vaccine uptake in cancer patients
Mar 16, 2023
Higher rates of vaccination were seen in older patients; lower rates were seen for metastatic solid tumors, with comorbidities.
COVID-19 vaccination linked to lower risk for postinfection outcomes
Mar 13, 2024
A reduced risk was seen for venous thromboembolism, arterial thrombosis/thromboembolism and heart failure.
Evidence updated on myocarditis after mRNA COVID-19 vaccination
Aug 02, 2022
The incidence of myocarditis is probably higher after vaccination with mRNA-1273 (Moderna) versus BNT162b2 (Pfizer) and lower with an increased interval between doses.
FDA advisers say next round of COVID-19 booster shots should target an XBB Variant
Jun 15, 2023
Protection against the original strain of the virus will be dropped from the updated vaccines as it could contribute to lower vaccine efficacy against newer strains.